Please use this identifier to cite or link to this item: http://hdl.handle.net/20.500.12779/6142
Title: Efficacy and toxicity of the antimicrobial peptide M33 produced with different counter-ions.
Authors: Pini, Alessandro
Lozzi, Luisa
Bernini, Andrea 
Brunetti, Jlenia
Falciani, Chiara
Scali, Silvia
Bindi, Stefano
DI MAGGIO, Tiziana
Rossolini, GIAN MARIA
Niccolai, Neri 
Bracci, Luisa
Issue Date: 2012
Project: None 
Journal: AMINO ACIDS
Abstract: 
The tetra-branched peptide M33 (Pini et al. in FASEB J 24:1015-1022, 2010) is under evaluation in animal models for its activity as antimicrobial agent in lung infections and sepsis. The preclinical development of a new drug requires medium-scale manufacture for tests of efficacy, biodistribution, pharmacokinetics and toxicity. In order to produce the most suitable peptide form for these purposes, we evaluated the behaviour of the peptide M33 obtained with different counter-ions. We compared activity and toxicity in vitro and in vivo of the peptide M33 produced as trifluoroacetate salt (TFacetate) and as acetate salt. The two forms did not differ substantially in terms of efficacy in vitro or in vivo but showed different toxicities for human cells and in animals. M33-TFacetate proved to be 5-30% more toxic than M33-acetate for cells derived from normal bronchi and cells carrying ΔF508 mutation in the CFTR gene, the most frequent variant in cystic fibrosis. M33-TFacetate produced manifest signs of in vivo toxicity immediately after administration, whereas M33-acetate only generated mild signs, which disappeared within a few hours. The peptide M33-acetate proved more suitable for the development of a new drug, and was therefore chosen for further characterization.
Description: 
40196
URI: http://hdl.handle.net/20.500.12779/6142
ISSN: 0939-4451
DOI: 10.1007/s00726-011-1103-z
Appears in Collections:Publications

Show full item record

Page view(s)

389
Last Week
0
Last month
137
checked on May 9, 2021

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.